Kongressbericht vom 31. Annual San Antonio Breast Cancer Symposium von 10.–14.12.2008

Zusammenfassung

Das 31. San Antonio Breast Cancer Symposium bestätigte den seit Jahren bestehenden Trend weg von risikoorientierter Behandlung hin zur maßgeschneiderten Diagnostik und Therapie des Mammakarzinoms. Wie auch in den vergangenen Jahren wurden zu gleichen Teilen Ergebnisse aus der Grundlagenforschung und Präklinik sowie klinische Studien vorgestellt und diskutiert. Neben den klassischen Themen wie antihormoneller, zielgerichteter Therapie und Chemotherapie standen in diesem Jahr auch disseminierte Tumorzellen im wissenschaftlichen Fadenkreuz. Immer wieder wurde auf Unterschiede in der primären Tumorentstehung im Gegensatz zur Metastasierung (Metastasensuppressorgene, Unterschiede im Ansprechen bestimmter Therapeutika in der adjuvanten oder palliativen Situation) hingewiesen. Im Bereich der antihormonellen Therapie der postmenopausalen Patientin zeigten die Aromatasehemmer erneut ihre therapeutische Überlegenheit gegenüber Tamoxifen bei zum Teil deutlich mehr Nebenwirkungen. Auch für upfront in der Adjuvanz eingesetztes Letrozol konnte in der Intention-to-treat-Analyse der BIG-1-98-Studie kein Gesamtüberlebensvorteil gezeigt werden. Nachdem in der TEAM-Studie auch für Exemestan ein Vorteil im Ansprechen gegenüber Tamoxifen demonstriert werden konnte, wird unser Upfront-Portefeuille um diese Substanz erweitert. Bei der Vorstellung der 36-Monate-Follow-up-Daten der ZOFAST-Studie konnte die signifikant geringere Knochendichteabnahme bei Zoledronsäurebehandlung bestätigt sowie ein signifikant besseres krankheitsfreies Überleben demonstriert werden. Dafür scheinen, das haben andere Studien (AZURE) bestätigt, direkte tumordestruierende Wirkungen zuständig zu sein. Im Bereich der Chemotherapie und der zielgerichteten Therapien konnte jetzt erstmalig auch in der Neoadjuvanz gezeigt werden, dass die Kombination von Chemotherapie und Trastuzumab neben einer deutlichen Ansprechverbesserung auch mit einer Prognoseverbesserung verbunden ist. Bei metastasierten Patienten erhärten sich die Fakten für einen Nutzen der Therapie mit Trastuzumab jenseits des Progresses. Wie bereits für andere Antikörper und Small Molecules konnte auch für Lapatinib die Überlegenheit in einer Kombination mit Letrozol im Gegensatz zur Monotherapie mit Letrozol bei metastasierten Her-2/neu hormonrezeptorpositiven Patienten gezeigt werden. Neue Substanzen wie Neratanib, ein Pan-ErbB-Tyrosinkinase-Hemmer und T‐DM1 (ein Konjugatwirkstoff aus Trastuzumab und Deacetylmaytansin, einem Spindelgift) wurden in ersten Studien getestet und verdienen eine weitere wissenschaftliche Beschäftigung.

Abstract

The 31th San Antonio Breast Cancer Symposium confirmed the development away from risk-oriented therapies towards tailored diagnostics and treatment in breast cancer. As in the preceding years, results presented at the meeting focused equally on basic research and on preclinical and clinical studies. Disseminated tumor cells were a “hot topic” across such diverse areas as endocrine therapy, chemotherapy and targeted therapy. Additionally, differences in the origin of primary tumors and of metastases (metastasis suppressor genes and the differential response to therapy in an adjuvant and an advanced setting) were elucidated and discussed in specific review sessions. In the field of postmenopausal adjuvant endocrine therapy, aromatase inhibitors demonstrated their therapeutic superiority to tamoxifen, with concomitantly higher rates of side effects. The upfront use of letrozole in the BIG 1-98 study also failed to show a significant benefit in overall survival in the intention-to-treat analysis. According to the results of the TEAM trial, exemestane appears to be a further option for upfront endocrine treatment in postmenopausal breast cancer patients. The 36 month follow-up data of the ZOFAST trial confirmed a significantly lower decline in bone mineral density after treatment with zoledronate and demonstrated an improvement in disease-free survival. This could be attributed to a direct anti-tumor effect of zoledronate (AZURE). Neoadjuvant therapy using a combination of trastuzumab and chemotherapy in Her-2+ patients demonstrated significantly higher response rates and should therefore become a standard therapy. In advanced Her-2+ breast cancer patients, the benefit of treatment with trastuzumab after disease progression was confirmed. As already demonstrated for other small molecules and antibodies, the combination of lapatinib and letrozole is another option for hormone receptor and Her-2/neu positive metastasized breast cancer patients. New drugs such as Neratanib (a pan-tyrosine kinase inhibitor) or T‐DM1 (a conjugate drug of Trastuzumab linked to deactyl maytansine) have demonstrated promising therapeutic effects and merit further investigation in breast cancer.

Brustkrebs - endokrine Therapie - Chemotherapie - zielgerichtete Therapie - Therapieresistenz

breast cancer - endocrine therapy - chemotherapy - targeted therapy - resistance to therapy

Literatur

• 1 Chlebowski R T, Kuller L, Anderson G. et al . Breast cancer after stopping estrogen plus progestin in postmenopausal women in the Women's Health Initiative.  Cancer Res. 2009;  69 (Suppl. 2)
• 2 Marshall S F, Chang E, Clarke C A. et al . Hormone therapy use before diagnosis and breast cancer survival in the California teachers study.  Cancer Res. 2009;  69 (Suppl. 2)
• 3 Cuzick J, Warwick J, Pinney L. et al . Change in breast density as a biomarker of breast cancer risk reduction; results from IBIS‐1.  Cancer Res. 2009;  69 (Suppl. 2)
• 4 Cuzick J, Warwick J, Pinney E. et al . Tamoxifen and breast density in women at increased risk of breast cancer.  J Natl Cancer Inst. 2004;  96 621-628
• 5 Bundred N J, Kenemans P, Beckmann M W. et al . Effect of tibolone on breast cancer recurrence: LIBERATE trial bone sub-study.  Cancer Res. 2009;  69 (Suppl. 2)
• 6 Morrow M. The role of magnetic resonance imaging in the breast cancer patient.  Cancer Res. 2009;  69 (Suppl. 2)
• 7 Solin L J. et al . Relationship of breast magnetic resonance imaging to outcome after breast-conservation treatment with radiation for women with early-stage invasive breast carcinoma or ductal carcinoma in situ.  J Clin Oncol. 2008;  26 386-391
• 8 Houssami N. et al . Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer.  J Clin Oncol. 2008;  26 3248-3258
• 9 Berg W A. et al . Breast ultrasound in the screening and diagnosis of breast cancer.  Cancer Res. 2009;  69 (Suppl. 2)
• 10 Berg W A. et al . Combined Screening with ultrasound and mammography vs. mammography alone in women at elevated risk of breast cancer.  JAMA. 2008;  299 2151-2163
• 11 Sakurai T. et al . Can nipple-sparing mastectomy be an alternative to mastectomy? Over 10 years of follow up at a Japanese institution.  Cancer Res. 2009;  69 (Suppl. 2)
• 12 Gomez R E. et al . Sentinel node biopsy performed in the neoadjuvant setting for breast cancer: results from the I‐SPY Trial (CALGB 150007/150012 & ACRIN 6657).  Cancer Res. 2009;  69 (Suppl. 2)
• 13 Gimbergues P. et al . Sentinel lymph node biopsy after neoadjuvant chemotherapy in accuracy in breast cancer patients with a clinically negative axillay nodal status at presentation.  Cancer Res. 2009;  69 (Suppl. 2)
• 14 Barth Jr. R J. et al . A prospective, multi-institutional study of adjuvant radiation therapy after resection of malignant phyllodes tumors.  Cancer Res. 2009;  69 (Suppl. 2)
• 15 Ingle J N, Dowsett M, Cuzick J. et al . Aromatase inhibitors versus tamoxifen as adjuvant therapy for postmenopausal women with estrogen receptor positive breast cancer: meta-analyses of randomized trials of monotherapy and switching strategies.  Cancer Res. 2009;  69 (Suppl. 2)
• 16 Mouridsen H T, Giobbie-Hurder A, Mauriac L. et al . BIG 1–98: A randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer.  Cancer Res. 2009;  69 (Suppl. 2)
• 17 Coates A S, Keshaviah A, Thürlimann B. et al . Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.  J Clin Oncol. 2007;  25 486-492
• 18 Jakesz R, Gnant M, Griel R. et al . Tamoxifen and anastrozole as a sequencing strategy in postmenopausal women with hormone-responsive early breast cancer: updated data from the Austrian breast and colorectal cancer study group trial 8.  Cancer Research. 2009;  69 (Suppl. 1)
• 19 Jones S E, Seynaeve C, Hasenburg A. et al . Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer.  Cancer Res. 2009;  69 (Suppl. 2)
• 20 Hadji P, Ziller M, Kieback D. et al . Bone effects of exemestane vs. tamoxifen within the TEAM trial: results of a prospective randomized bone sub study.  Cancer Res. 2009;  69 (Suppl. 2)
• 21 Bartlett J MS, Brookes C L, Billingham L J. et al . A prospectively planned pathology study within the TEAM trial confirms that progesterone receptor expression is prognostic but is not predictive for differential response to exemestane versus tamoxifen.  Cancer Res. 2009;  69 (Suppl. 2)
• 22 Eidtmann H, Bundred N J, DeBoer R. et al . The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST.  Cancer Res. 2009;  69 (Suppl. 2)
• 23 Madlensky L, Flatt S W, Natarajan L. et al . Hot flashes are associated with CYP2D6 genotype in breast cancer survivors taking tamoxifen.  Cancer Res. 2009;  69 (Suppl. 2)
• 24 Goetz M, Ames M, Gnant M. et al . Pharmacogenetic (CYP2D6) and gene expression profiles (HOXB13/IL17BR and molecular grade index) for prediction of adjuvant endocrine therapy benefit in the ABCSG 8 trial.  Cancer Res. 2009;  69 (Suppl. 2)
• 25 Goetz M P, Suman V, Ames M. et al . Tamoxifen pharmacogenetics of CYP2D6, CYP2C19, and SULT1A1: long term follow-up of the North Central Cancer Treatment Group 89-30-52 adjuvant trial.  Cancer Res. 2009;  69 (Suppl. 2)
• 26 Gianni L, Eiermann W, Semiglazov V. et al . Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer: primary efficacy analysis of the NOAH trial.  Cancer Res. 2009;  69 (Suppl. 2)
• 27 von Minckwitz G, Kaufmann M, Kümmel S. et al . Integrated meta-analysis on 6402 patients with early breast cancer receiving neoadjuvant anthracycline-taxane ± Trastuzumab containing chemotherapy.  Cancer Res. 2009;  69 (Suppl. 2)
• 28 Joensuu H, Kellokumpu-Lehtinen P, Huovinen R. et al . Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T) 5-FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim analysis of the FinXX-trial.  Cancer Res. 2009;  69 (Suppl. 2)
• 29 Swain S M, Jeong J-H, Geyer C E. et al . NSABP B‐30: definitive analysis of patient outcome from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer.  Cancer Res. 2009;  69 (Suppl. 2)
• 30 McArthur H L, Rugo H, Nulsen B. et al . Cardiac safety of adjuvant bevacizumab (B) plus dose-dense doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel (nab-P) in patients with early stage breast cancer.  Cancer Res. 2009;  69 (Suppl. 2)
• 31 Miller K, Wang M, Gralow J. et al . Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.  N Engl J Med. 2007;  357 2666-2676
• 32 Miles D, Chan A, Romieu G. et al . Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO.  J Clin Oncol. 2008;  26 (Suppl.)
• 33 Conte P, Roche H, Perez E. et al . Ixabepilone plus capecitabine improves overall survival in symptomatic patients with metastatic breast cancer previously treated with anthracycline and taxane in 2 large phase III studies.  Cancer Res. 2009;  69 (Suppl. 2)
• 34 Vahdat L, Fein L E, Karwal M W. et al . Ixabepilone plus capecitabine vs. capecitabine in patients with metastatic breast cancer receiving ixabepilone in the first line setting: a pooled analysis from two phase III studies.  Cancer Res. 2009;  69 (Suppl. 2)
• 35 Perez E, Pivot X, Vrdoljak E. et al . A prospective characterization of the resolution of ixabepilone induced peripheral neuropathy: data from a large registrational program in patients with metastatic breast cancer.  Cancer Res. 2009;  69 (Suppl. 2)
• 36 Von Minckwitz G, Zielinski C, Maarteense E. et al . Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3–05).  J Clin Oncol. 2008;  26 (Suppl.)
• 37 Rugo H, Kaufman P, Tan-Chiu E. et al . Survival of patients with HER2+ metastatic breast cancer and use of trastuzumab following progression: analysis of RegistHER.  Cancer Res. 2009;  69 (Suppl. 2)
• 38 Bachelot T, Lluch A, Gutierrez M. et al . Activity and safety of sunitinib in combination with trastuzumab for the treatment of metastatic breast cancer: initial results from a phase II study.  Cancer Res. 2009;  69 (Suppl. 2)
• 39 Burstein H J, Sun Y, Tan A R. et al . Neratinib (HKI‐272), an irreversible pan erbB receptor tyrosine kinase inhibitor: phase 2 results in patients with advanced HER2+ breast cancer.  Cancer Res. 2009;  69 (Suppl. 2)
• 40 Liu H, Possinger K, Eucker J. Combination of carboplatin and the mTor inhibitor RAD001 is a new therapeutic approach for p 53-mutated breast cancer.  Cancer Res. 2009;  69 (Suppl. 2)
• 41 Fasolo A, Gianni L, Rorive A. et al . Multicenter phase I clinical trial of daily and weekly RAD001 (everolimus) in combination with vinorelbine and trastuzumab in patients with HER‐2-overexpressing metastatic breast cancer with prior resistance to trastuzumab.  Cancer Res. 2009;  69 (Suppl. 2)